XML 69 R40.htm IDEA: XBRL DOCUMENT v3.20.4

Acquisition and Variable Interest Entity - Additional Information (Detail) $ in Thousands, ¥ in Millions			1 Months Ended		12 Months Ended
	Sep. 15, 2020 USD ($)	Sep. 15, 2020 CNY (¥)	Jul. 31, 2020 USD ($)	Jul. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 CNY (¥)
Beijing Falikang Pharmaceutical Co. Ltd [Member]
Acquisition And Variable Interest Entity [Line Items]
Percentage of outstanding shares owned					51.10%	51.10%
Investment | $					$ 2,825
Beijing Falikang Pharmaceutical Co. Ltd [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]
Acquisition And Variable Interest Entity [Line Items]
Investment					2,800	¥ 19.2
FibroGen Beijing [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member]
Acquisition And Variable Interest Entity [Line Items]
Percentage of outstanding shares acquired						48.90%
Cash consideration					$ 1,400	¥ 8.9
Percentage of outstanding shares owned					51.10%	51.10%
Falikang's total registered capital | ¥						¥ 17.5
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member]
Acquisition And Variable Interest Entity [Line Items]
Percentage of outstanding shares acquired				100.00%
Cash consideration			$ 2,100	¥ 15.0
Transaction costs | ¥				5.0
Acquisition costs			400	¥ 2.5
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | Acquired License [Member]
Acquisition And Variable Interest Entity [Line Items]
Entire purchase price | $			$ 2,500
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | AstraZeneca AB [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member]
Acquisition And Variable Interest Entity [Line Items]
Percentage of outstanding shares sold in exchange for cash consideration	48.90%	48.90%
Cash consideration for exchange of outstanding shares	$ 1,000	¥ 7.3
Percentage of outstanding shares owned	51.10%	51.10%

X

- Definition

Acquisition and variable interest entity line items.

+ References

No definition available.

+ Details

Name:	fgen_AcquisitionAndVariableInterestEntityLineItems
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity method investment additions.

+ References

No definition available.

+ Details

Name:	fgen_EquityMethodInvestmentAdditions
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of outstanding shares of acquiree sold by acquirer.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer
Namespace Prefix:	fgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Percentage of voting equity interests acquired at the acquisition date in the business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of total capital as defined by regulatory framework.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 948
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 505
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 948
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998

+ Details

Name:	us-gaap_Capital
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of the entity's equity method investment which has been sold.

+ References

No definition available.

+ Details

Name:	us-gaap_EquityMethodInvestmentSoldCarryingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 5A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685

+ Details

Name:	us-gaap_VariableInterestEntityOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AcquiredLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: